key: cord-0878949-rytw6rfd
authors: Tada, Takuya; Zhou, Hao; Dcosta, Belinda M.; Samanovic, Marie I.; Mulligan, Mark J.; Landau, Nathaniel R.
title: The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies
date: 2021-05-16
journal: bioRxiv
DOI: 10.1101/2021.05.14.444076
sha: 44cf4878c603bc93982e3898955bd5c056e790b0
doc_id: 878949
cord_uid: rytw6rfd

Highly transmissible SARS-CoV-2 variants recently identified in India designated B.1.617 and B.1.618 have mutations within the spike protein that may contribute to their increased transmissibility and that could potentially result in re-infection or resistance to vaccine-elicited antibody. B.1.617 encodes a spike protein with mutations L452R, E484Q, D614G and P681R while the B.1.618 spike has mutations Δ145-146, E484K and D614G. We generated lentiviruses pseudotyped by the variant proteins and determined their resistance to neutralization by convalescent sera, vaccine-elicited antibodies and therapeutic monoclonal antibodies. Viruses with B.1.617 and B.1.618 spike were neutralized with a 2-5-fold decrease in titer by convalescent sera and vaccine-elicited antibodies. The E484Q and E484K versions were neutralized with a 2-4-fold decrease in titer. Virus with the B.1.617 spike protein was neutralized with a 4.7-fold decrease in titer by the Regeneron monoclonal antibody cocktail as a result of the L452R mutation. The modest neutralization resistance of the variant spike proteins to vaccine elicited antibody suggests that current vaccines will remain protective against the B.1.617 and B.1.618 variants.

Despite efforts to contain severe acute respiratory syndrome coronavirus-2 (SARS-CoV-44 2) the virus has continued to spread throughout the world's population, generating novel 45 variants with mutations selected for immunoevasion and increased transmissibility. The 46 variants contain point mutations and short deletions in the spike protein driven by 47 neutralization. D145-146 lies in the N-terminal domain that is a known antibody binding 67 site [18] and P681R lies within S1/S2 where it could affect proteolytic processing (Fig. 1A  68 and B). Which of the mutations contributes to increased ACE2 affinity and resistance to 69 antibody neutralization that might account for the increased transmissibility of the variants 70

is not well understood. 71

In this study, we addressed the questions of antibody resistance and variant spike protein 73 affinity for ACE2 using lentiviruses pseudotyped by the B.1.617 and B.1.618 spike 74 proteins. We found that the viruses with the Indian spike proteins were partially resistant 75 to neutralization by convalescent serum antibody and vaccine-elicited antibodies. The 76 resistance was caused by the L452R, E484Q and E484K mutations. In addition, the 77 variants were partially resistant to REGN10933, one of the two mAbs constituting the 78 Regeneron COV2 therapy. to D614G and the P681R mutation near the proteolytic processing site (Fig. 1A and B) . 85

The B.1.618 spike has E484K in the RBD in addition to D614G and the N-terminal deletion 86 D145-146 ( Fig. 1A and B) . We constructed expression vectors for the B.1.617 and 87 B.1.618 spike proteins and for spike proteins with the individual point mutations and used 88 these to produce lentiviral pseudotypes that with a genome encoding GFP and luciferase 89

reporters. Immunoblot analysis of transfected cells and supernatants showed that the 90 variant spike proteins were expressed and proteolytically processed and that the spike 91 proteins were incorporated into lentiviral virions at a level similar to that of wild-type 92 D614G ( Supplementary Fig. 1) . Quantification of the band intensities showed that the 93 P681R mutation, which lies near the proteolytic processing site, caused a small increase 94 in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2. Analysis 95 of the infectivity of each virus, normalized for particle number, on ACE2.293T cells 96

showed that the B.1.617 spike protein (L452R/E484Q/P681R) was >2-fold increase in 97 infectivity while B.1.618 was similar to wild-type D614G. Analysis of the individual 98 mutations showed that the increased infectivity of the B.1.617 spike was attributed to 99 L452R, which itself caused a 3.5-fold increase in infectivity and in combination with 100 E484Q caused a 3-fold increase. The other individual point mutations had no significant 101 effect on infectivity (D145-146, E484K, P681R) (Fig. 1C) . Analysis of the same panel of 102 each spike protein with an overall decrease of 50-fold infectivity. 104 105 Neutralization of the Indian variants by convalescent sera and vaccine-elicited 106 antibody. To determine the sensitivity of the Indian variants to antibody neutralization, 107

we tested the serum specimens from convalescent patients who had been infected prior 108 to the emergence of the variants for neutralization of the panel of pseudotyped viruses. 109

The results showed that viruses with the B.1.617 and B.1.618 spikes were 2.3 and 2.5-110 fold resistant to neutralization by convalescent sera compared to wild type -a finding that 111 was similar to that of the 3-fold resistance of the South Africa B.1.351 variant ( Fig. 2A) . 112

The resistance of B. The results showed a similar pattern of resistance to neutralization as for the 120 convalescent sera except that overall antibody titers were about 5-fold higher for sera 121 from vaccinated individuals. B.1.617 was about 4-fold-resistant and B.1.618 was about 122 2.7-fold resistant to neutralization. The resistance could be attributed to L452R and 123 E484Q in B.1.617 and E484K in B.1.618 (Fig. 2B) . transmissibility of the variants could be caused by increased affinity for ACE2 as has been 141 found for other variants. To determine the relative ACE2 affinities of the variant spikes, 142

we used an ACE2 binding assay in which the pseudotyped viruses were incubated with 143 soluble ACE2 (sACE2) and then tested for infectivity on ACE2.293T cells relative to that 144 of virus with the D614G mutation, an assay that we have used previously to analyze 145 variant spike protein affinity [11] . The assay shows a 6-fold increase in ACE2 affinity for 146 the N501Y mutation, a result consistent with that reported previously (Fig. 4) . The results 147

showed only a small effect for the single E484K mutations but a larger effect for variants 148 with the L452R or combination of E484Q and L452R. The P681R and D145-146 had no 149 effect. 150

Viruses with the B.1.617 and B.1.618 spike were partially resistant to neutralization, with 152 an average 3.9-fold and 2.7-fold decrease in IC50 for convalescent sera and antibodies 153 elicited by Pfizer and Moderna mRNA vaccines, respectively. The neutralization written consent under IRB approved protocols (IRB 18-02035 and IRB 18-02037). Donor 210 age and gender were not reported. Regeneron monoclonal antibodies (REGN10933 and 211 REGN10987) were prepared as previously described [21] . 212

reported [21] . Viruses were concentrated by ultracentrifugation and normalized for 216 reverse transcriptase (RT) activity. To determine neutralizing antibody titers, sera or 217 mAbs were serially diluted 2-fold and then incubated with pseudotyped virus 218 (approximately 2.5 X 10 7 cps) for 30 minutes at room temperature and then added to 219 ACE2.293T cells. Luciferase activity was measured as previously described [22] . 220 221

Serially diluted recombinant soluble ACE2 protein [22] was incubated with pseudotyped 223 virus for 30 minutes at room temperature and added to 1 X 10 4 ACE2.293T cells. After 2 224 days, luciferase activity was measured using Nano-Glo luciferase substrate (Nanolight) 225

in an Envision 2103 microplate luminometer (PerkinElmer). 226 227

Spike proteins were analyzed on immunoblots probed with anti-spike mAb (1A9) 229 (GeneTex), anti-p24 mAb (AG3.0) and anti-GAPDH mAb (Life Technologies) followed by 230 goat anti-mouse HRP-conjugated second antibody (Sigma) as previously described [22] . 231 232

All experiments were in technical duplicates or triplicates and the data were analyzed 234 using GraphPad Prism 8. Statistical significance was determined by the two-tailed, 235 unpaired t-test. Significance was based on two-sided testing and attributed to p< 0.05. 

The authors declare no competing interests. 254 

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral 306 immunity

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor 309 plasma

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Convergent 314 evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second 315 wave of COVID-19 in Maharashtra

A neutralizing human 318 antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

 figure  379